Biotechnology company Novavax is kicking off its phase one clinical trial of a vaccine that combines both the seasonal flu inoculation and a vaccination for the coronavirus.
Novavax is behind one of the stand-alone vaccines for the coronavirus and it has announced it has participants ready to undertake trials of a combined vaccine.
Gregory Glenn, the president of research and development at Novavax, said the study is the first of its kind to try and see whether the combined vaccine is able to “induce a robust immune response” against two diseases at the same time.
“The combination of these two vaccines, which have individually delivered outstanding results with favorable safety and tolerability profiles, may lead to greater efficiencies for the healthcare system and achieve high levels of protection against COVID-19 and influenza with a single regimen,” Glenn said.
The trial will involve 650 healthy adults between the ages of 50 to 70 and each participant will either have been previously infected by COVID-19 or vaccinated with an authorised vaccine at least eight weeks before they commence involvement in the trial.
News of Novavax’s trial of a combined vaccination follows recent announcements by the Australian Therapeutic Goods Administration’s provisional approval for the use of Moderna to vaccinate people between 12 and 17 years of age.
That September 4 announcement said that the two doses of Moderna for people between 12 and 17 years of age would be taken 28 days apart – that is the same as the interval between doses for adults.
Moderna was granted provisional approval for the use of its vaccine known as Spikevax for people 18 years and over on August 9.